ArticleBiotechnology journal2025
Optimizing Lentiviral Vector Production: Insights Into PiggyBac Transposase and Concatemeric Array Strategies.
Article in Biotechnology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Optimizing Lentiviral Vector Production: Insights Into PiggyBac Transposase and Concatemeric Array Strategies.Biotechnology journal · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lentiviral vectors (LVVs) are essential tools in gene and cell therapy due to their ability to transduce both dividing and non-dividing cells. Conventional production by transient plasmid co-transfection is variable, costly, and difficult to scale, prompting development of stable producer cell lines. Historically, the GPRTG cell line has been generated using concatemeric-array integration, which requires high DNA input, complex workflows, and can cause genetic instability. To address these limitations, we evaluated a transposase-mediated integration strategy. Compared with the concatemeric-array method, transposase-based integration enabled faster recovery after selection with only a mild viability crisis and required substantially less DNA. This approach generated highly diverse and heterogeneous producer pools, providing a strong basis for subsequent clonal selection. During LVV production, both methods maintained comparable cell growth stability. However, concatemeric-derived pools exhibited greater variability in recovery kinetics, viable cell density, and LVV titers, despite achieving the highest maximum titers overall. In contrast, transposase-mediated pools showed more consistent performance, supporting their reliability for large-scale applications. In summary, transposase-based integration offers a robust and scalable alternative to concatemeric-array methods for generating stable LVV producer cell lines, with significant potential to streamline LVV manufacturing for gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.